BerGenBio $BGBIO.OL rallies amid Norwegian biotech optimism
BerGenBio
BGBIO
is a norwegian clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.
The stock is currently in a short term uptrend that could provide a new test of important resistance, where a breakout to the upside could trigger a powerful buy signal.
Sponsored analyst summary:
https://www.trinitydelta.org/research-notes/bemcentinib-nsclc-data-continues-to-impress/
Twitter:
https://twitter.com/bgenbio
Investor Relations:
https://www.bergenbio.com/investors/
BGBIO
is a norwegian clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The stock is currently in a short term uptrend that could provide a new test of important resistance, where a breakout to the upside could trigger a powerful buy signal.
Sponsored analyst summary:
https://www.trinitydelta.org/research-notes/bemcentinib-nsclc-data-continues-to-impress/
Twitter:
https://twitter.com/bgenbio
Investor Relations:
https://www.bergenbio.com/investors/
